Avadel Pharmaceuticals plc (AVDL) Presents at Morgan Stanley 23rd Annual Global Healthcare

Sean Laaman
Head of Healthcare Research & Equity Analyst

Welcome to Morgan Stanley Global Healthcare Conference. I’m Sean Laaman, Head of U.S. mid-cap biotech Equity Research here at the firm. Before we begin, research disclosure website at www.morganstanley.com/researchdisclosures. And if you have any questions, please reach out to your Morgan Stanley sales representative. For this session, we have Avadel. We have CEO, Greg Divis; CFO, Tom McHugh; and COO, Susan Rodriguez. So welcome to the 3 of you.

Before we commence the broader Q&A, maybe if we could get a high-level view of Avadel.

Thomas McHugh
Senior VP, Principal Financial & Accounting Officer and CFO

Yes. First of all, thanks for having us here and the opportunity to participate in your conference. It’s much appreciated. Avadel is a growing biotech company that has really transformed itself in the last 5-plus years.

We’re now in our ninth quarter of our launch of LUMRYZ, a first and only once-at-bedtime oxybate for the treatment of narcolepsy for patients suffering from EDS and cataplexy, both adults and pediatrics. But it’s a very dynamic and exciting time for us right now as we just — we’re in the middle of our ninth quarter of continuing adding more patients and growing our business and growing prescribers with over 3,100 patients on LUMRYZ.

We’ve moved into the cash flow positive state as a commercial stage organization. We’re in the back end of our pivotal Phase III trial for an indication expansion in idiopathic hypersomnia, which we